Gunnar Houge1, Alv Johan Skarbøvik. 1. Kompetansesenteret for Fabry sykdom, Senter for medisinsk genetikk og molekylaermedisin, Haukeland Universitetssjukehus, 5021 Bergen. gunnar.houge@helse-bergen.no
Abstract
BACKGROUND: Fabry disease, unlike most other metabolic diseases, is prone to familiar and regional clustering because of X-linked inheritance and normal fertility in affected men. Affected individuals can be offered intravenous enzyme replacement therapy. MATERIALS AND METHODS: In two counties in western Norway there are 41 affected individuals, giving a minimum prevalence of the disease of 1 in 17,000. The patient material is briefly presented. We discuss some of the administrative and financial challenges that this type of diseases present in our public health system. RESULTS AND INTERPRETATION: The great variability in disease expression and severity within and between families delays the diagnosis and necessitates a broad clinical follow up of affected persons. A false diagnosis is often made (e.g. MS, irritable colon, a psychiatric disorder, idiopathic hypertrophic cardiomyopathy, or kidney failure). The follow up regime is briefly described, with special emphasis on the practical and financial implications of enzyme replacement therapy in Norway.
BACKGROUND:Fabry disease, unlike most other metabolic diseases, is prone to familiar and regional clustering because of X-linked inheritance and normal fertility in affected men. Affected individuals can be offered intravenous enzyme replacement therapy. MATERIALS AND METHODS: In two counties in western Norway there are 41 affected individuals, giving a minimum prevalence of the disease of 1 in 17,000. The patient material is briefly presented. We discuss some of the administrative and financial challenges that this type of diseases present in our public health system. RESULTS AND INTERPRETATION: The great variability in disease expression and severity within and between families delays the diagnosis and necessitates a broad clinical follow up of affected persons. A false diagnosis is often made (e.g. MS, irritable colon, a psychiatric disorder, idiopathic hypertrophic cardiomyopathy, or kidney failure). The follow up regime is briefly described, with special emphasis on the practical and financial implications of enzyme replacement therapy in Norway.
Authors: Miroslav Vujasinovic; Bojan Tepes; Bojan Vujkovac; Andreja Cokan Vujkovac; Martin Tretjak; Vesna Korat Journal: Wien Klin Wochenschr Date: 2015-04-03 Impact factor: 1.704
Authors: Deepak Acharya; Peter Robertson; G Neal Kay; Leslie Jackson; David G Warnock; Vance J Plumb; José A Tallaj Journal: Clin Cardiol Date: 2012-08-09 Impact factor: 2.882
Authors: Ju Huang; Aneal Khan; Bryan C Au; Dwayne L Barber; Lucía López-Vásquez; Nicole L Prokopishyn; Michel Boutin; Michael Rothe; Jack W Rip; Mona Abaoui; Murtaza S Nagree; Shaalee Dworski; Axel Schambach; Armand Keating; Michael L West; John Klassen; Patricia V Turner; Sandra Sirrs; C Anthony Rupar; Christiane Auray-Blais; Ronan Foley; Jeffrey A Medin Journal: Mol Ther Methods Clin Dev Date: 2017-05-12 Impact factor: 6.698
Authors: Doris Klingelhöfer; Markus Braun; Rebekka K Seeger-Zybok; David Quarcoo; Dörthe Brüggmann; David A Groneberg Journal: Mol Genet Genomic Med Date: 2020-02-07 Impact factor: 2.183